International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populationsDan H. Barouch, Jaap Goudsmit, Hannah Kibuuka et al.|Vaccine|2011Cited by 308
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Nelson L. Michael, Leyi Lin et al.|The Lancet|2017Cited by 196
First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)Lindsey R. Baden, Dan H. Barouch, Stephen R. Walsh et al.|The Journal of Infectious Diseases|2012Cited by 168
Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)Dan H. Barouch, Lindsey R. Baden, Jinyan Liu et al.|The Journal of Infectious Diseases|2012Cited by 107
Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donorVincent Dussupt, Nelson L. Michael, Rajeshwer S. Sankhala et al.|Nature Medicine|2020Cited by 88